Research Divisions, Labs & Researchers
Department of Immunology and Genomic Medicine
Our laboratory was the global pioneer in advocating PD-1 antibody-based cancer immunotherapy. Achieving a better understanding of the fundamental biology behind checkpoint inhibitors in human cancer models will help us to build better therapy regimes and enhance the efficiency and effectivity of cancer immunotherapy.
Division of Integrated High-Order Regulatory Systems
Our goal is to build the basic tools for future immune system intervention in cancer and other diseases through research on immune system interactions in health and disease, using advanced proteomics and metabolomics tools.
Division of Clinical Immunology and Cancer Immunotherapy
We use immune adverse events in cancer immunotherapy together with bio-makers as model systems to better understand and predict the likelihood of success as well as risk factors of cancer immunotherapy in various types of cancer.
Division of Cancer Immunotherapy
Our goal is to develop next generation cancer immunotherapies that enhance the efficacy of PD-1 blockade. We will maximize immune activation at tumor sites using a two sided approach, i.e. unique innate immunity-activating adjuvant and enhanced tumor destruction.
Multi-Omics Platform
Together with our collaborators at Kyoto University and in industry, we have been building a powerful new multi-omics platform to accelerate research into interactions between cancer and the immune system. This platform is available to all scientists at CCII and Kyoto University.
Visiting Researchers
Our goal at CCII is to work closely with organizations in academia and industry in Japan and abroad. Already today, CCII is hosting numerous of scientists from industry or overseas research organizations in visiting positions. CCII’s new research building will provide special facilities for visiting scientists.
Akio Ohta
